BIETTI CRYSTALLINE DYSTROPHY
Clinical trials for BIETTI CRYSTALLINE DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new BIETTI CRYSTALLINE DYSTROPHY trials appear
Sign up with your email to follow new studies for BIETTI CRYSTALLINE DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy trial offers hope for rare blinding eye disease
Disease control OngoingThis early-stage study is testing whether a new gene therapy called VGR-R01 is safe for people with Bietti Crystalline Dystrophy, a rare genetic eye disease that causes vision loss. The trial will enroll 12 adults to receive a single injection into the eye and monitor them closel…
Matched conditions: BIETTI CRYSTALLINE DYSTROPHY
Phase: PHASE1 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Gene therapy trial aims to halt vision loss in rare eye disease
Disease control OngoingThis study is testing whether a one-time gene therapy injection called VGR-R01 can slow or stop vision loss in adults with Bietti Crystalline Dystrophy, a rare inherited retinal disease. It will enroll 45 participants, with two-thirds receiving the therapy in one eye and the rest…
Matched conditions: BIETTI CRYSTALLINE DYSTROPHY
Phase: PHASE3 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC